Health
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is
About this update from Cytokinetics, Incorporated
[{"type":"image","alt":"Cytokinetics, Incorporated","displaySize":"","headline":null,"caption":"Cytokinetics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":131,"url":"https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/krzaXZKRQxBvrYt6O7t_yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/10a960ea96a50bea5c777e88dba3bc2e","width":300,"height":131}},"lazy":false},{"type":"text","content":"European Commission Approval Based on Results of SEQUOIA-HCM","length":60,"tagName":"p"},{"type":"text","content":"First European Launch Expected in Germany in Q2 2026","length":52,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction.","length":611,"tagName":"p"},{"type":"text","content":"“The approval of MYQORZO in the European Union is an important milestone towards bringing this medicine to more patients living with obstructive HCM around the world,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are pleased that the European label allows providers flexibility to determine whether a patient starts treatment at either 5 mg or 10 mg, based on the severity of their baseline LVOT obstruction. We look forward to making MYQORZO available in Europe, beginning with our first launch in Germany in the second quarter of this year.”","length":576,"tagName":"p"},{"type":"text","content":"“Myosin inhibition is establishing itself as an important therapy that may improve the lives of patients with hypertrophic obstructive cardiomyopathy. The approval of aficamten by the European Commission brings another treatment option into our clinical practice, allowing for more treatment flexibility t...